| Literature DB >> 35098037 |
Michelle Mendanha Mendonça1, Kellen Rosa da Cruz1, Denise da Silva Pinheiro1, Gean Carlos Alves Moraes1, Patricia Maria Ferreira1, Marcos Luiz Ferreira-Neto2, Eduardo Sérgio da Silva3, Reggiani Vilela Gonçalves4, Gustavo Rodrigues Pedrino1, James O Fajemiroye1, Carlos Henrique Xavier5.
Abstract
Introduction: The evolving COVID-19 pandemic became a hallmark in human history, not only by changing lifestyles, but also by enriching scientific knowledge on viral infection and its consequences. Objective: Although the management of cardiorespiratory changes is pivotal to a favorable prognosis during severe clinical findings, dysregulation of other systems caused by SARS-CoV-2 infection may imbalance erythrocyte dynamics, such as a bidirectional positive feedback loop pathophysiology. Method andEntities:
Keywords: COVID-19; Erythrocyte; Hemoglobin; Hemorphins; SARS-CoV-2
Year: 2022 PMID: 35098037 PMCID: PMC8786672 DOI: 10.1016/j.htct.2022.01.005
Source DB: PubMed Journal: Hematol Transfus Cell Ther ISSN: 2531-1379
Figure 1Hypothetical feedback loop oxidative mechanism resulting in, and from, erythrocyte death. The SARS-CoV-2 infection would activate metabolic processes inside the host cell and in inflammatory/immune systems that would result in an imbalanced redox status. Oxidative stress affects erythrocytes, thus inducing death of these red blood cells. The release of free iron, as a direct consequence of this erythrocyte destruction, would facilitate the metabolic reactions underlying the oxidative stress. The major structural proteins of SARS-CoV-2 interacting with host cells are spike (S), membrane (M) and envelope (E). Angiotensin-converting enzyme type 2 (ACE-2) and serine protease 2 (TMPRSS2) are the host cell membrane proteins interacting with SARS-CoV-2 proteins. Alpha and Beta are the hemoglobin chains released following erythrocyte death, from which bioactive peptides are derived. ROS: reactive oxygens species.
Figure 2Slide from a critically ill patient with COVID-19 admitted to an intensive care unit of a hospital. The slide details evidence of morphological alterations in red blood cells by the SARS-CoV-2 infection: red - mushroom red blood cells; green - red blood cells with the presence of Heinz bodies; blue - dacryocytes; purple - spherocytes; yellow - echinocytes (plasmolysis), and; black - acanthocytes; orange - keratocytes (bite cell). Staining method: Leishman. Magnification: 400X. Credits: Dr. Denise da Silva Pinheiro - LACES-ICB UFG.
Figure 3Hypothetical mechanisms underlying the SARS-CoV-2-induced formation of Heinz Bodies as a clinical sign of hematological alteration that may occur through two possible routes, as represented by black arrows. The SARS-CoV-2 infection may affect the membrane Band-3-anchored multiprotein complex, thus resulting in erythrocyte damages. Furthermore, the SARS-CoV-2 infection may interfere with the early hematopoiesis processes in the bone marrow, resulting in the production and release of immature erythrocytes, the so-called reticulocytes. Therefore, this red blood cell maturation would be impaired by the viral infection, thus reducing the chances of producing a healthy erythrocyte, which may culminate in either reticulocyte death or its bizarre morphophysiological maturation.
Figure 4Slide highlighting Heinz bodies from a critically ill patient with COVID-19 admitted to an intensive care unit of a hospital. Staining method: Brilliant Cresyl Blue. Magnification: 400X. Credits: Dr. Denise da Silva Pinheiro - LACES-ICB UFG.
Bioactive peptides derived from the α-globin and β-globin chain of hemoglobin.
| Source | |||
|---|---|---|---|
| Hbα | Neokiotorphin | Thr-Ser-Lys-Tyr-Arg | |
| Hbα | kiotorphin | Tyr-Arg | |
| Hbα | Hemopressin | Pro-Val-Asn-Phe-Leu-Ser-His | |
| Hbα | RVD-Hpα | Val-Asp-Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His | |
| Hbα | VD-Hpα | Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Phe-Leu-Ser-His | |
| Hbβ | 35-38 | Hemorphin-4 | Tyr-Pro-Trp-Thr |
| Hbβ | 35-39 | Hemorphin-5 | Tyr-Pro-Trp-Thr-Gln |
| Hbβ | 35-40 | Hemorphin-6 | Tyr-Pro-Trp-Thr-Gln-Arg |
| Hbβ | 35-41 | Hemorphin-7 | Tyr-Pro-Trp-Thr-Gln-Arg-Phe |
| Hbβ | 33-38 | VV-hemorphin-4 | Val-Val-Tyr-Pro-Trp-Thr |
| Hbβ | 33-39 | VV-hemorphin-5 | Val-Val-Tyr-Pro-Trp-Thr-Gln |
| Hbβ | 33-40 | VV-hemorphin-6 | Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg |
| Hbβ | 33-41 | VV-hemorphin-7 | Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe |
| Hbβ | 32-38 | LVV-hemorphin-4 | Leu-Val-Val-Tyr-Pro-Trp-Thr |
| Hbβ | 32-39 | LVV-hemorphin-5 | Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln |
| Hbβ | 32-40 | LVV-hemorphin-6 | Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg |
| Hbβ | 32-41 | LVV-hemorphin-7 | Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe |
| Hbβ | VD-Hpβ | Val-Asp-Pro-Glu-Asn-Phe-Arg-Leu-Leu-Cys-Asn-Met |
Source: Da CRUZ, 2016.